NPS Executes On Ultra-Orphan Gattex Launch With FDA Approval In Hand
Executive Summary
NPS Pharmaceuticals will price the short bowel syndrome treatment at $295,000 per year – in line with the cost of other drugs in the ultra-orphan spectrum and higher than some industry observers expected – but said the addressable patient population is lower than it previously estimated.